Request Demo

Last update 08 May 2025

SCARA5

Last update 08 May 2025

Basic Info

Synonyms

FLJ23907, MGC45780, NET33

+ [3]

Introduction

Ferritin receptor that mediates non-transferrin-dependent delivery of iron. Mediates cellular uptake of ferritin-bound iron by stimulating ferritin endocytosis from the cell surface with consequent iron delivery within the cell. Delivery of iron to cells by ferritin is required for the development of specific cell types, suggesting the existence of cell type-specific mechanisms of iron traffic in organogenesis, which alternatively utilize transferrin or non-transferrin iron delivery pathways. Ferritin mediates iron uptake in capsule cells of the developing kidney. Preferentially binds ferritin light chain (FTL) compared to heavy chain (FTH1).

Drugs associated with SCARA5

WO2024230638

Patent Mining

Target

SCARA5

Mechanism-

Active Org.

The Ninth People's Hospital of Shanghai Jiaotong University Medical College

Originator Org.

The Ninth People's Hospital of Shanghai Jiaotong University Medical College

Active Indication

Eye Diseases, Hereditary [+2]

Inactive Indication-

Drug Highest PhaseDiscovery

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

100 Clinical Results associated with SCARA5

100 Translational Medicine associated with SCARA5

0 Patents (Medical) associated with SCARA5

110

Literatures (Medical) associated with SCARA5

01 May 2025·Genomics

Heterogeneity of fibroblasts from different anatomical sites in healthy human knee ligaments revealed by single-cell RNA sequencing

Article

Author: Yao, Yizhi ; Xiao, Xiao ; Jiang, Fan ; Zhao, Haibo ; Yu, Tengbo ; Zhu, Xuesai

Knee ligaments are important structures that determine the locomotor function of the knee. In this paper, we identified and analyzed the cell types and compositions of ligaments from different parts of the healthy knee joint. By single-cell sequencing of approximately 106,077 extracted cells, we established a comprehensive cellular profile of ligaments in other parts of the knee joints of 15 healthy subjects and explored the more critical heterogeneity of fibroblasts. Three subpopulations of fibroblasts that may be associated with knee ligament anatomy were identified and their differentiation relationships were revealed, and the FTH1/FTL_SCARA5 signaling pathway that may be associated with knee ligament anatomical function was identified. This ligament atlas provides a molecular cytological basis for studying the physiological functions and properties of knee ligaments as well as the relationship between ligament structure and function at different sites. It offers certain clues for future studies of rated knee ligament diseases.

01 May 2025·Cellular Signalling

SCARA5 deficiency inhibits ferroptosis via regulating iron homeostasis and results in sorafenib resistance in hepatocellular carcinoma

Article

Author: Li, Lin ; Han, Ze-Guang ; Chen, Cong ; Shang, Xu-Yang ; Wang, Lan ; Cui, Xiao-Fang ; Bai, Shi-Hao ; Wang, Na

SCARA5 (Scavenger Receptor Class A Member 5), a member of scavenger receptor class A, is a type II transmembrane protein. Previous studies, including our own, have suggested that SCARA5 acts as a tumor suppressor in various cancers. Additionally, SCARA5 has been identified as a ferritin receptor that facilitates iron delivery independent of transferrin. However, it remains unclear whether ferroptosis is involved in the tumor-suppressive function of SCARA5 in hepatocellular carcinoma (HCC). In this study, we found that SCARA5-deficient cells, including mouse embryonic fibroblasts (MEFs) and HCC cells, exhibited reduced sensitivity to ferroptosis induced by erastin and RSL3. We measured the cell viability, cellular reactive oxygen species (ROS), lipid ROS, malondialdehyde (MDA) and ferrous iron concentration to assess the role of SCARA5 in ferroptosis. Mechanistically, we confirmed that SCARA5 might enhance the intracellular availability of bioactive ferrous iron by promoting autophagic degradation of the major iron storage protein ferritin. Furthermore, we found that SCARA5 deficiency contributed to the resistance of HCC cells to sorafenib, a therapeutic agent for HCC, possibly by inhibiting ferroptosis. Collectively, our study revealed the role of SCARA5 in regulating ferroptosis, providing a profound understanding of sorafenib resistance in HCC systemic therapy.

01 Apr 2025·Acta Biomaterialia

DNA nanovaccines derived from ferritin-modified glycogens for targeted delivery to immature dendritic cells and for promotion of Th1 cell differentiation

Article

Author: Lu, Jinjin ; Li, Sichen ; Liang, Jing ; Zhou, Juan ; Zhang, Yan ; Chen, Jinghua ; Wu, Jun ; Gao, Min

DNA vaccines have emerged as a powerful approach for advanced cancer therapy. Despite the development of various delivery systems to enhance the immunogenicity of DNA vaccines, many still face challenges such as limited DNA condensation, rapid degradation in vivo and insufficient targeting to lymph nodes (LNs). Synthetic dendrimers with modifiable surfaces exhibit high efficiency in DNA condensation, but their synthesis is extremely complex. This study utilizes cationic glycogen, a natural branched dendrimer-like polymer, as the core structure for efficient DNA condensation and delivery, ensuring good biocompatibility. By connecting ferritin light chain to the glycogen surfaces, active targeting of LNs can be achieved due to its affinity for the SCARA5 receptor on immature dendritic cells (DCs), facilitating vaccine migration to the LNs. In addition, a seperate plasmid encoding adjuvant IL-12 was co-delivered to further boost the immunogenicity of the DNA nanovaccine. In vivo and in vitro experiments confirmed the effective transfection capability of this DNA vaccine, demonstrating promoted DC maturation, increased antigen presentation, and Th1 cell differentiation, resulting in improved anti-tumor efficiency in vivo. This innovative multi-gene co-loaded DNA vaccine offers valuable insights into combined gene therapy and broadens the research horizon on non-viral gene carriers. STATEMENT OF SIGNIFICANCE: The DNA vaccine encounters challenges such as limited DNA condensation, rapid degradation and insufficient targeting to lymph nodes (LNs), resulting in generally weak immunogenicity. In the current study, a novel nanovaccine is developed by connecting ferritin light chain to natural dendrimer glycogen, for simultaneous delivery of dual plasmids. The cationized glycogen provides strong DNA condensation ability, while ensuring excellent stability of the nanovaccine. The presence of ferritin light chain leads to effective targeting of dendritic cells (DCs), facilitating its migration to LNs. Moreover, the plasmid encoding the adjuvant IL-12 is co-incorporated with the antigen plasmid to mitigate the immunosuppression environment. This strategy significantly improves the immunogenicity of DNA vaccines, demonstrating high efficiency in cancer immunotherapy.

Analysis

Perform a panoramic analysis of this field.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

SCARA5

Basic Info

Related

Analysis